Recent projections could create an environment of unprecedented demand for nuclear imaging.

Bayer’s latest contrast agent is proving its potential in clinical trials as a promising alternative to agents with higher gadolinium content. 

New survey data indicate that addressing the effect of technologists’ missed opportunities during their training may be a yearslong effort.